


## **Valve Industry Veteran, Todd Campbell joins ValveXchange as Senior Executive Director of Product Development.**

**January 17, 2011. Denver** - ValveXchange Inc. is pleased to announce that Mr. Todd Campbell has joined the VXi team to direct product development and help the company achieve its First-in-Man (FIM) milestone. Todd Campbell is a Medical Device Industry professional, technical visionary, entrepreneur, leader, and is skilled in operations, project management and executive leadership in the development of life saving medical devices. Todd was the first to join ValveXchange many years ago when Dr. Vesely founded the company; while both were developing the exchangeable valve concept on a part-time basis. Mr. Campbell served as the Principle Investigator on ValveXchange's first 2 NIH SBIR grants, and continued to work with ValveXchange through its recent scale up in R&D efforts. Over the past two years, Mr. Campbell and has been instrumental in establishing the valve assembly methodology, the procurement of pericardium, Dacron<sup>®</sup> and suture material, and the training of assembly technicians. With ValveXchange now moving toward a "First-in-Man" study during 2011, Todd Campbell has joined the Executive Team of ValveXchange on a full-time basis to take on the role of Senior Executive Director of Product Development.



Todd's career spans over 30 years, with most of his effort in the bioprosthetic heart valve field. He has held Operations, R&D, Regulatory and Quality roles for several heart valve and cardiovascular companies including Hancock Laboratories - the first US manufacturer of bioprosthetic valves; St. Jude Medical, where he managed tissue technologies and bioscience (1991-1995); and Sadra Medical - a percutaneous heart valve start-up company (acquired by Boston Scientific) as their VP of Research and Development and co-Chief Operations Officer. At Sadra, he led the redesign of the valve and took it to its First-in-Man study. He also served as VP of R&D for Hansen Medical (2006-2008) during the time that they were developing the AorTx transcatheter valve technology. Todd previously held R&D roles at Medtronic AVE as Senior R&D Engineer where he managed the development of novel coronary stent and catheter technologies incorporating molecular, cellular and biological therapies for treating arterial, coronary and vascular diseases. Mr. Campbell founded and led Medtronic's initial effort in drug eluting stents and pioneered the initial studies into biodegradable stent technologies as alternatives to conventional drug-eluting stents. As Sr. Research Chemist and COO of Tissue Implants at Baxter (Edwards) Healthcare (1980-1991), Todd developed anticalcification treatments to improve the clinical longevity of bioprosthetic heart valves.

Mr. Campbell received his undergraduate degree in Biological Sciences from the University of California, Irvine and his graduate degrees in Molecular Biology and Engineering from California State University, Fullerton. Mr. Campbell has been involved with entrepreneurial start-up organizations over the last 10 years. His efforts have been recognized by Popular Science, with the award of best new medical device in 2003 (for the HemCon<sup>®</sup> Bandage) and also recognized by the US Army for best new medical device in 2004. Mr. Campbell is named inventor on twenty-five patents and patent applications, with twelve of these in the cardiovascular and interventional cardiology field. Mr. Campbell is the recipient of two NIH SBIR grants for heart valves and two Medtronic Corporate Quest grants for advanced stent designs. He has authored multiple strategic business plans for entrepreneurial companies, and founded Millipede<sup>®</sup> (military and civilian podiatry devices) and Endolumen Therapeutics (vulnerable plaque devices). Mr. Campbell continues to be involved in International organizations providing expert sourcing of bovine pericardium from GBR 1 countries (Australia and New Zealand), and professional consulting to medical device companies in China, Thailand, Australia and Israel.